Evidence map›Paper›PMID 27765729›Full record

Observational studyClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2017

Infection With Hepatitis C Virus Genotype 3 Is an Independent Risk Factor for End-Stage Liver Disease, Hepatocellular Carcinoma, and Liver-Related Death.

Brian J McMahon, Dana Bruden, Lisa Townshend-Bulson, Brenna Simons, Phillip Spradling, Stephen Livingston, James Gove, Annette Hewitt, Julia Plotnik, Chriss Homan and 6 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 3 pooled it
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 3 syntheses or guidelines pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Frontiers in microbiology · 2024
    Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Brian J McMahonLiver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, Alaska; Arctic Investigations Program, Division of Preparedness and Emerging Infections, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control, Anchorage, Alaska. Electronic address: bdm9@cdc.gov.
Dana BrudenArctic Investigations Program, Division of Preparedness and Emerging Infections, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control, Anchorage, Alaska.
Lisa Townshend-BulsonLiver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, Alaska.
Brenna SimonsLiver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, Alaska.
Phillip SpradlingDivision of Viral Hepatitis, Centers for Human Immunodeficiency Virus, Tuberculosis Prevention, Sexually Transmitted Diseases, and Viral Hepatitis, Centers for Disease Control, Atlanta, Georgia.
Stephen LivingstonLiver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, Alaska.
James GoveLiver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, Alaska.
Annette HewittLiver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, Alaska.
Julia PlotnikLiver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, Alaska.
Chriss HomanLiver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, Alaska.
Hannah EsperaLiver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, Alaska.
Susan NegusLiver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, Alaska.
Mary SnowballLiver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, Alaska.
Youssef BarbourLiver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, Alaska.
Michael BruceArctic Investigations Program, Division of Preparedness and Emerging Infections, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control, Anchorage, Alaska.
Prabhu GounderArctic Investigations Program, Division of Preparedness and Emerging Infections, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control, Anchorage, Alaska.
Alaska Native Tribal Health Consortium · USNational Center for Emerging and Zoonotic Infectious Diseases · US

Funding

The Administrative CoreP20GM103395 · NIGMS · UNIVERSITY OF ALASKA FAIRBANKS · PI STACY M. RASMUS · 2012 to 2026
$66.1M
NATURAL HISTORY PREVENTION OF VIRAL HEPATITIS IN ALASKA NATIVE PEOPLEU01PS001097 · PS · ALASKA NATIVE TRIBAL HEALTH CONSORTIUM · PI MCMAHON, BRIAN JAMES · 2008 to 2012
$1.3M
AHRQ HHS T32 HS000046NCHHSTP CDC HHS U01 PS001097NIGMS NIH HHS P20 GM103395
6 · The paper itself

Abstract

BACKGROUND &

aimsFew studies have examined factors associated with disease progression in hepatitis C virus (HCV) infection. We examined the association of 11 risk factors with adverse outcomes in a population-based prospective cohort observational study of Alaska Native/American Indian persons with chronic HCV infection.

methodsWe collected data from a population-based cohort study of liver-related adverse outcomes of infection in American Indian/Alaska Native persons with chronic HCV living in Alaska, recruited from 1995 through 2012. We calculated adjusted hazard ratios (aHR) and 95% confidence intervals (CIs) for end-stage liver disease (ESLD; presence of ascites, esophageal varices, hepatic encephalopathy, or coagulopathy), hepatocellular carcinoma (HCC), and liver-related death using a Cox proportional hazards model.

resultsWe enrolled 1080 participants followed up for 11,171 person-years (mean, 10.3 person-years); 66%, 19%, and 14% were infected with HCV genotypes 1, 2, and 3, respectively. On multivariate analysis, persons infected with HCV genotype 3 had a significantly increased risk of developing all 3 adverse outcomes. Their aHR for ESLD was 2.1 (95% CI, 1.5-3.0), their aHR for HCC was 3.1 (95% CI, 1.4-6.6), and their aHR for liver-related death was 2.4 (95% CI, 1.5-4.0) compared with genotype 1. Heavy alcohol use was an age-adjusted risk factor for ESLD (aHR, 2.2; 95% CI, 1.6-3.2), and liver-related death (aHR, 2.9; 95% CI, 1.8-4.6). Obesity was a risk factor for ESLD (aHR, 1.4; 95% CI, 1.0-1.9), and diabetes was a risk factor for ESLD (aHR, 1.5; 95% CI, 1.1-2.2). Male sex was a risk factor for HCC (aHR, 3.6; 95% CI, 1.6-8.2).

conclusionsIn a population-based cohort study of American Indian/Alaska Native persons with chronic HCV infection, we found those infected with HCV genotype 3 to be at high risk for ESLD, HCC, and liver-related death.

Indexed as

GenotypeAdultAlaskaAlaska NativesCarcinoma, HepatocellularDisease ProgressionEnd Stage Liver DiseaseFemaleHepacivirusHepatitis C, ChronicHumansIndians, North AmericanMaleMiddle AgedProspective StudiesRisk FactorsAK-HEPCAmerican Indian/Alaska NativeHepatitis C OutcomeLiver Cancer Risk

Identifiers

PMID27765729
PMCPMC5316337
OpenAlexW2533261646

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.